Clene Inc., a clinical‑stage biotechnology firm listed on Nasdaq, closed a registered direct offering of common stock on Monday that generated $4 million in gross proceeds. The securities were sold at market price under Nasdaq rules and the transaction was executed without a placement agent, underwriter, broker or dealer.
The offering was led by Chairman David Matlin and included participation from the company’s chief executive officer, other existing shareholders and founding investor Kensington Capital Holdings. All shares were sold to insiders, reflecting confidence in the company’s near‑term prospects.
Clene said the proceeds will fund operations through the middle of the first quarter of 2027, a period that extends beyond a pending FDA decision on the acceptance of its New Drug Application for CNM‑Au8, an investigational therapy for amyotrophic lateral sclerosis (ALS) under the accelerated approval pathway.
The company also disclosed that, should the FDA accept the NDA for review, it could raise an additional $6.7 million to $7.8 million through common stock warrants in a financing planned for January 2026, further extending its cash runway.
Clene’s pipeline focuses on neurodegenerative diseases, including ALS, Parkinson’s disease and multiple sclerosis, with CNM‑Au8 targeting mitochondrial function to improve central‑nervous‑system cell survival and function.
